Research peptide comparison

BPC-157 vs TB-500: Research Comparison

BPC-157 and TB-500 are two of the most widely studied peptides in tissue-repair research, and they are often mentioned together. They are very different molecules: BPC-157 is a 15-amino-acid fragment of a gastric protein, while TB-500 is related to thymosin beta-4, a 43-amino-acid actin-binding protein. This page compares their origin, structure, proposed mechanisms and the research behind each.

BPC-15715 aa · ≈ 1419.5 Da

TB-500 (Tβ4)43 aa · ≈ 4963 Da

Shared fieldTissue repair

Found together inGLOW & KLOW

Compare side by side ↓How they differ ↓

For in vitro research use only. Not for human or animal use. Nothing on this page is medical advice.

The short answer

Both peptides are studied in tissue-repair models, but they come from different proteins and are linked to different mechanisms:

• BPC-157 is a stable 15-amino-acid peptide derived from a protein in gastric juice. Research focuses on angiogenesis (new blood vessel formation), the nitric oxide system and gastrointestinal models.
• TB-500 is related to thymosin beta-4 (Tβ4), a protein found in almost every cell. Research focuses on actin regulation and cell migration, with work in wound, corneal and cardiac models.

In short: BPC-157 is mainly studied for vascular and gastrointestinal effects, TB-500 for cell movement and structural repair. Neither is an approved medicine.

Side-by-side comparison

Chemical data

The name “TB-500” is used loosely in the market: some suppliers use it for the full 43-amino-acid protein and others for a short 7-amino-acid fragment (Ac-LKKTETQ). The TB-500 we supply is full-length thymosin beta-4. See our TB-500 guide for the difference.

Proposed mechanisms

The key difference is the starting point: BPC-157 research centres on blood vessels and the nitric oxide system, while thymosin beta-4 research centres on the actin cytoskeleton, the internal scaffold cells use to move and change shape.

Research areas compared

Based on the volume of published preclinical research. “Extensive” refers to the number of studies, not to proven effects.

Strength of the evidence

• BPC-157Most published work comes from one research group at the University of Zagreb, almost all in rodent models. Published human data are minimal: a small case series and an early-phase trial whose results were not fully reported.
• Thymosin beta-4Studied by many independent groups, including a widely cited 2004 Nature paper on cardiac repair. Full-length Tβ4 has been tested in a small number of early-phase clinical studies. The short 7-amino-acid fragment has no published human trials.

Why they are studied together

Because they act through different mechanisms in overlapping research areas, BPC-157 and thymosin beta-4 are often combined in experimental work to explore whether vascular and cell-migration pathways interact. Both are components of our pre-mixed research blends:

Limitations of the evidence

• Almost all data for both peptides come from cell and animal models; results do not necessarily translate to humans.
• There are no large, randomised, controlled human trials for either compound.
• Very few studies compare BPC-157 and thymosin beta-4 directly, or test them in combination.
• Findings for full-length thymosin beta-4 cannot be assumed to apply to short “TB-500” fragments.
• Reviewers have raised theoretical safety questions for both, linked to their effects on blood-vessel growth and cell proliferation.

Quality and testing

Every batch of BPC-157 and TB-500 we supply is independently tested for purity by Janoshik using HPLC before it is released for sale. Read more on our Quality & Testing page.

Regulatory status

Neither BPC-157 nor TB-500 (thymosin beta-4) is approved as a medicine by the MHRA, FDA or EMA. Both are on the World Anti-Doping Agency (WADA) Prohibited List. Sterling Research supplies both strictly as research reagents for in vitro laboratory use, not for human or animal use.

Storage and handling in the lab

• Store lyophilised powder at −20 °C, sealed and protected from light and moisture.
• Let the vial reach room temperature before opening to limit condensation.
• Prepare solutions to your laboratory’s validated protocols, with appropriate PPE and aseptic technique.
• Avoid repeated freeze–thaw cycles of solutions; aliquot where your protocol allows.

Order BPC-157 or TB-500

Both peptides are available for laboratory research through our official store, sterling-research.com.

Related research compounds

Frequently asked questions

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid peptide derived from a gastric protein and is mainly studied for angiogenesis and the nitric oxide system. TB-500 is related to thymosin beta-4, a 43-amino-acid protein that binds actin and is mainly studied for cell migration. Both are researched in tissue-repair models.

Is TB-500 the same as thymosin beta-4?

Not always. “TB-500” is a trade name used for both full-length thymosin beta-4 (43 amino acids) and a short 7-amino-acid fragment of it. The TB-500 we supply is full-length thymosin beta-4.

Which has more research behind it, BPC-157 or TB-500?

Thymosin beta-4 has been studied by more independent research groups and has reached a few early-phase clinical studies. BPC-157 has a large number of animal studies, but most come from a single research group, and human data are minimal.

Why are BPC-157 and TB-500 often studied together?

They act through different mechanisms (vascular and nitric oxide pathways for BPC-157, actin and cell migration for thymosin beta-4) in overlapping research areas, so combining them lets researchers explore how these pathways interact. Both are included in the GLOW and KLOW research blends.

Are BPC-157 and TB-500 approved for human use?

No. Neither is approved as a medicine by the MHRA, FDA or EMA, and both are prohibited in sport by WADA. They are supplied strictly for in vitro laboratory research.

References

1. Seiwerth S, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972–1989.
2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323–333.
3. Bock-Marquette I, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432:466–472.
4. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51.

This page is for scientific information only. Sterling Peptides Ltd supplies BPC-157 and TB-500 strictly for in vitro laboratory research. Not for human or animal use, and not for diagnostic or therapeutic purposes. Questions: contact@sterling-research.com